New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
17:18 EDTIDXXIDEXX announces FTC preliminary approval of consent agreement
IDEXX Laboratories announced that the commissioners of the U.S. FTC have preliminarily approved the consent agreement previously reached between the company and the staff of the FTC Bureau of Competition. Pursuant to FTC protocol, a proposed draft complaint and the proposed consent agreement, which includes a draft consent order, will be placed on public record for a 30-day comment period, after which the FTC will evaluate any public comment before finalizing the agreement and order. "While we admit no wrongdoing and continue to believe that our distribution practices do not violate the antitrust laws as these same practices have been upheld in previous litigation victories, this is another important step toward final resolution of the multi-year FTC investigation, which we now expect to occur early in 2013," the company said.
News For IDXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:13 EDTIDXXIDEXX sees FY15 adjusted EPS $4.38-$4.48, consensus $4.33
Subscribe for More Information
07:12 EDTIDXXIDEXX raises FY14 adjusted EPS to $3.85-$3.90 from $3.79-$3.86, consensus $3.82
Subscribe for More Information
07:09 EDTIDXXIDEXX to incur transitional impacts in 2014 related to all-direct sales strategy
The company estimates that transition impacts in aggregate will reduce 2014 revenue by $18M-$23M and 2014 operating profit and EPS by $31M-$37M and 40c-47c, respectively. These impacts include a drawdown of distributor inventories in the fourth quarter that the company now expects will result in a one-time reduction in revenue and operating profit of approximately $18M-$23M and $15M-$19M, respectively. The higher end of the estimated impact range corresponds with the full estimated impact of the inventory drawdown impact related to the move to the all-direct sales strategy. The transition impacts also include $6M in incremental expense as the Company ramps up sales and operating resources ahead of the transition, and $10M-$12M associated with project management and other one-time costs required to implement the strategy.
07:07 EDTIDXXIDEXX reports Q3 Companion Animal Group organic revenue growth 13%
Subscribe for More Information
07:07 EDTIDXXIDEXX: US Companion Animal Diagnostics sales transformation acceleration
Subscribe for More Information
07:06 EDTIDXXIDEXX reports Q3 adjusted EPS $1.05, consensus 90c
Subscribe for More Information
October 23, 2014
15:39 EDTIDXXNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use